Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04581382 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03784625 | Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012(MELRIV-1) | completed | Early Phase 1 | 10 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02320305 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | completed | Early Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02316795 | Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | completed | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01748747 | Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01568996 | Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions | completed | Early Phase 1 | 17 | John KirkwoodOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00972933 | Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma | completed | Early Phase 1 | 59 | Diwakar DavarOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01209676 | IMCgp100 in Advanced Unresectable Melanoma | completed | Early Phase 1 | 1 | University of PennsylvaniaOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01425749 | Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI(Mel55) | completed | Early Phase 1 | 25 | Craig L Slingluff, JrOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00276835 | Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer | completed | Early Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00470379 | Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00436410 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | completed | Early Phase 1 | 108 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 2, 2012 | clinicaltrials |
| NCT00580060 | Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity | completed | Early Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00743353 | Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5(K5) | completed | Early Phase 1 | 16 | Siemens Molecular ImagingINDUSTRY | 1 | Feb 2, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2026source: clinicaltrials